Cantor Fitzgerald Initiation Sends Silence Therapeutics Stock Higher Ahead of Pivotal Divesiran Readout
Silence Therapeutics PLC shares jumped sharply after Cantor Fitzgerald began coverage with an Overweight rating, highlighting divesiran's potential and assigning a 75% probability of success for the Phase 2 SANRECO trial in polycythemia vera. The move added institutional visibility to a stock already supported by Buy-equivalent ratings from other b…